Favorable Results for DOAC After Peripheral Intervention

]]>(MedPage Today) -- People who took rivaroxaban (Xarelto) after lower-extremity revascularization for peripheral artery disease (PAD) enjoyed fewer subsequent major adverse limb and cardiovascular events, according to the VOYAGER PAD trial.The...